Targeting XIAP and PPARγ in Granulosa Cell Tumors Alters Metabolic Signaling

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Ovarian granulosa cell tumors (GCTs) are indolent, hormonally active cancers with no effective therapies.
• X-linked inhibitor of apoptosis protein (XIAP) and peroxisome proliferator-activated receptor gamma (PPARγ) are overexpressed in GCTs.
• XIAP normally inhibits PPARγ, promoting cancer cell proliferation.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting XIAP to restore PPARγ signaling in GCTs.
• To identify downstream targets of PPARγ activation in GCT cells.

Main Methods:

• Utilized a SMAC-mimetic (Compound A) to inhibit XIAP and rosiglitazone/retinoic acid to activate PPARγ in KGN GCT cells.
• Employed stable isotope labeling with amino acids in cell culture (SILAC) to identify differentially expressed proteins.
• Performed in silico screening and chromatin immunoprecipitation (ChIP) to confirm PPARγ binding to the stearoyl-CoA desaturase (SCD) promoter.

Main Results:

• XIAP inhibition and PPARγ restoration reduced proliferation and induced apoptosis in KGN cells.
• 32 differentially expressed proteins were identified, with 22 upregulated by ≥1.5 fold.
• Stearoyl-CoA desaturase (SCD) showed a 4.5-fold induction and direct PPARγ binding to its promoter was confirmed.

Conclusions:

• Inhibiting XIAP reactivates PPARγ signaling, leading to anti-cancer effects in GCTs.
• Upregulation of metabolic enzymes like SCD is a consequence of restored PPARγ activity.
• This strategy presents a promising therapeutic avenue for ovarian granulosa cell tumors.